• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    2/14/24 5:04:02 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email
    SC 13G/A 1 ea193832-13ga7gov_kamada.htm AMENDMENT NO. 7 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*

     

    Kamada Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value NIS 1.0 per share

    (Title of Class of Securities)

     

    M6240T 109
    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    1

     

     

    CUSIP No. M6240T 109

     

     

    1

     

    NAME OF REPORTING PERSON: Gov Financial Holdings Ltd.

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): Not applicable.

     

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions):

    (a) ☐

    (b) ☐

     

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION: Israel

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER: -0- Ordinary Shares

     

     

    6

     

    SHARED VOTING POWER: 1,511,406 Ordinary Shares*

     

     

    7

     

    SOLE DISPOSITIVE POWER: -0- Ordinary Shares

     

     

    8

     

    SHARED DISPOSITIVE POWER: 1,511,406 Ordinary Shares*

     

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 1,511,406 Ordinary Shares*

     

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)        ☐

     

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 2.63%**

     

     

    12

     

    TYPE OF REPORTING PERSON: CO

     

     

     

    *Gov Financial Holdings Ltd. (“Gov”) is wholly-owned by Mr. Leon Recanati, who exercises sole voting and investment power over the shares held by Gov.

     

    **Calculated based on 57,479,528 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    2

     

     

    CUSIP No. M6240T 109

     

     

    1

     

    NAME OF REPORTING PERSON: Insight Capital Ltd.

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): Not applicable.

     

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions):
    (a) ☐

    (b) ☐

     

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION: Israel

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER: -0- Ordinary Shares

     

     

    6

     

    SHARED VOTING POWER: 1,346,335 Ordinary Shares*

     

     

    7

     

    SOLE DISPOSITIVE POWER: -0- Ordinary Shares

     

     

    8

     

    SHARED DISPOSITIVE POWER: 1,346,335 Ordinary Shares*

     

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 1,346,335 Ordinary Shares*

     

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)        ☐

     

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 2.34%**

     

     

    12

     

    TYPE OF REPORTING PERSON: CO

     

     

     

    *

    Insight Capital Ltd. (“Insight”) is wholly-owned by Mr. Leon Recanati, who exercises sole voting and investment power over the shares held by Insight.

     

    **

    Calculated based on 57,479,528 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    3

     

     

    CUSIP No. M6240T 109

     

     

    1

     

    NAME OF REPORTING PERSON: Leon Recanati

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): Not applicable.

     

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions):
    (a) ☐

    (b) ☐

     

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION: Israel

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER: 678,520 Ordinary Shares

     

     

    6

     

    SHARED VOTING POWER: 2,857,741 Ordinary Shares*

     

     

    7

     

    SOLE DISPOSITIVE POWER: 678,520 Ordinary Shares

     

     

    8

     

    SHARED DISPOSITIVE POWER: 2,857,741 Ordinary Shares*

     

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 3,536,261 Ordinary Shares*

     

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)        ☐

     

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 6.15%**

     

     

    12

     

    TYPE OF REPORTING PERSON: IN

     

     

     

    *Mr. Recanati directly holds 631,145 ordinary shares of the Issuer and options to purchase 47,375 ordinary shares of the Issuer currently exercisable or exercisable within 60 days of December 31, 2023. In addition, Mr. Recanati beneficially owns 1,511,406 ordinary shares of the Issuer through Gov and 1,346,335 ordinary shares of the Issuer through Insight, both of which are wholly-owned by Mr. Leon Recanati.

     

    **Calculated based on 57,479,528 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    4

     

     

    CUSIP No. M6240T 109

     

    Item 1.

     

    (a)Name of Issuer: Kamada Ltd.

     

    (b)Address of Issuer’s Principal Executive Offices:

    2 Holzman St., Science Park,

    P.O. Box 4081,

    Rehovot, 7670402, Israel

     

    Item 2.

     

    (a)Name of Person Filing:

    Gov Financial Holdings Ltd.

    Leon Recanati

     

    I.R.S. Identification No. of above person (entities only): N/A

     

    (b)Address of Principal Business Office or, if none, Residence:

    27 Yoav St. 69081, Israel

     

    (c)Citizenship: Israel

     

    (d)Title of Class of Securities: Ordinary Shares, par value NIS 1.0 per share (“Ordinary Shares”)

     

    (e)CUSIP Number: M6240T 109

     

    Item 3.Not applicable

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

    Gov Financial Holdings Ltd. 1,511,406 Ordinary Shares

    Insight Capital Ltd. 1,346,335

    Leon Recanati 678,520 Ordinary Shares

     

    (b)Percent of class:

    Gov Financial Holdings Ltd. 2.63%*

    Insight Capital Ltd. 2.34%*

    Leon Recanati 6.15%*

     

    *Calculated based on 57,479,528 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    (c)Number of shares as to which person has:

     

    (i)Sole power to vote or to direct the vote: See Item 5 of each cover page.

     

    (ii)Shared power to vote or to direct the vote: See Item 6 of each cover page.

     

    (iii)Sole power to dispose or to direct the disposition of: See Item 7 of each cover page.

     

    (iv)Shared power to dispose or to direct the disposition of: See Item 8 of each cover page.

     

    *Calculations are based on 57,479,528 Ordinary Shares of the Issuer outstanding as of December 31, 2023.

     

    5

     

      

    CUSIP No. M6240T 109

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    Not applicable.

     

    6

     

     

    CUSIP No. M6240T 109

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      /s/ Leon Recanati
      By: Gov Financial Holdings Ltd.
      Name:   Leon Recanati
      Title: Chairman and CEO
       
      /s/ Leon Recanati
      By: Insight Capital Ltd.
      Name:   Leon Recanati
      Title: Chairman and CEO
       
      /s/ Leon Recanati
      By: Leon Recanati

     

    7

     

     

    CUSIP No. M6240T 109

     

    EXHIBIT NO.   DESCRIPTION
         
    Exhibit 99.1   Joint Filing Agreement, dated February 14, 2024

     

     

    8

     

    Get the next $KMDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    SEC Filings

    View All

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    12/10/25 9:15:01 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    12/8/25 7:00:07 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by Kamada Ltd.

    6-K/A - KAMADA LTD (0001567529) (Filer)

    12/2/25 7:38:36 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Kamada with a new price target

    The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

    3/21/25 8:11:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Kamada with a new price target

    Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

    7/3/24 7:31:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

    Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026  Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho

    12/8/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

    Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub

    11/10/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

    REHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) to prevent late Cytomegalovirus ("CMV") infection, a common post-transplant infectious complication that remains an unaddressed medical need, despite recent advances in anti-viral drug therapies. The study, titled "Strategic H

    11/4/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Financials

    Live finance-specific insights

    View All

    Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

    Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026  Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho

    12/8/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

    Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub

    11/10/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

    REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties

    11/3/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    11/14/24 6:21:51 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/14/24 5:04:02 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/12/24 12:41:57 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

    Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

    8/30/23 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

    REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

    5/24/23 7:05:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care